ImageneBio, Inc. (IMA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.89 (-2.59%), Market cap $0.06B, 52-week low–high $1.14 ~ $17.90.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Financial statements, price targets, institutional (13F) holdings and related news for ImageneBio, Inc. are updated in real time on BlackAll Trade.
ImageneBio, Inc. trades at $4.89 (-2.59%). Real-time quotes and charts are available on BlackAll Trade.
ImageneBio, Inc. has a market cap of about $0.06B.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007,